RXST · NASDAQ
RxSight, Inc.
$5.02 +0.17 (+3.57%)
Company overview
RxSight, Inc. is a medical technology company that researches, develops, manufactures, and sells light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. The RxSight system enables doctors to customize and enhance visual acuity for patients after cataract surgery. It includes the RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision. The company primarily serves cataract surgeons. RxSight was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. It was incorporated in 1997 and is headquartered in Aliso Viejo, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $209M
- Employees
- 498
- Headquarters
- Aliso Viejo, CA
- Website
- rxsight.com
- CEO
- Ronald Kurtz
- Listed
- July 30, 2021
- P/E
- -4.44
- Dividend yield
- 0.00%
Company financials
- Revenue
- $127M
- Gross profit
- $98.2M
- Operating income
- -$55.3M
- EBITDA
- -$50.1M
- Net income
- -$46.6M
- EPS
- -$1.13
- Total assets
- $304M
- Total debt
- $10.8M
- Gross margin
- 77.02%
- Net margin
- -36.58%
- Earnings yield
- -22.51%
No geographic segmentation.
Showing FY 2025
RXST
1D
NASDAQ
O5.06H5.11L5.01C5.07-0.01 (-0.30%)Vol85.71K